Stress Urinary Incontinence - Opinion Divided on Drug Therapy

Table of Contents

• ABOUT DATAMONITOR HEALTHCARE
  • About the CNS pharmaceutical analysis team
• OVERVIEW
  • This product has been designed for delivery in a slidepack format (PowerPoint).
    • Please select the slide pack option from the downloadmenu at the side of the page
    • Introduction
    • Scope of this report
    • Research and analysis highlights
    • Key reasons to read this report
• APPENDIX A
  • Research methodology
  • Physician Sample breakdown
  • Urinary Incontinence and Overactive Bladder InsightStudy - Physician Questionnaire
    • Section One Overview of Urinary Incontinence andoveractive Bladder
      • Epidemiology
      • Presentation
      • Diagnosis
      • Referral pattern
    • Section Two Stress Urinary Incontinence
      • Diagnosis and treatment of SUI
      • Non-pharmacological treatment
      • Pharmacological treatment for SUI
    • Section Three Overactive Bladder With Urge Symptomsand/or Incontinence
      • Diagnosis and treatment of UUI
      • Pharmacological treatment for UUI
      • Diagnosis and treatment of 'dry OAB'
      • Pharmacological treatment for dry OAB
    • Section Four Mixed Stress/Urge Urinary Incontinence
      • Diagnosis and treatment of mixed SUI/UUI
      • Non-pharmacological treatment
      • Pharmacological treatment for mixed SUI/UUI
    • Section Five Interstitial Cystitis
      • Diagnosis and treatment of IC
      • Pharmacological treatment for IC
    • Section Six Drug Profiles
      • Section A: Drug influences on physicians' choice
      • Section B: The general treatment of urinary incontinenceand overactive bladder
  • Contributing experts
    • US
    • Japan
    • Europe
• APPENDIX B
  • About Datamonitor
    • About Datamonitor Healthcare
    • About the CNS analysis team
  • Disclaimer
• List of Tables
  • Table 1: Physician sample by country and respondenttype